Data from The G Protein–Coupled Receptor GPR30 Inhibits Proliferation of Estrogen Receptor–Positive Breast Cancer Cells

Abstract

<div>Abstract<p>The G protein–coupled receptor GPR30 binds 17β-estradiol (E<sub>2</sub>) yet differs from classic estrogen receptors (ERα and ERβ). GPR30 can mediate E<sub>2</sub>-induced nongenomic signaling, but its role in ERα-positive breast cancer remains unclear. Gene expression microarray data from five cohorts comprising 1,250 breast carcinomas showed an association between increased GPR30 expression and ERα-positive status. We therefore examined GPR30 in estrogenic activities in ER-positive MCF-7 breast cancer cells using G-1 and diethylstilbestrol (DES), ligands that selectively activate GPR30 and ER, respectively, and small interfering RNAs. In expression studies, E<sub>2</sub> and DES, but not G-1, transiently downregulated both ER and GPR30, indicating that this was ER mediated. In Ca<sup>2+</sup> mobilization studies, GPR30, but not ERα, mediated E<sub>2</sub>-induced Ca<sup>2+</sup> responses because E<sub>2</sub>, 4-hydroxytamoxifen (activates GPR30), and G-1, but not DES, elicited cytosolic Ca<sup>2+</sup> increases not only in MCF-7 cells but also in ER-negative SKBr3 cells. Additionally, in MCF-7 cells, GPR30 depletion blocked E<sub>2</sub>-induced and G-1–induced Ca<sup>2+</sup> mobilization, but ERα depletion did not. Interestingly, GPR30-coupled Ca<sup>2+</sup> responses were sustained and inositol triphosphate receptor mediated in ER-positive MCF-7 cells but transitory and ryanodine receptor mediated in ER-negative SKBr3 cells. Proliferation studies involving GPR30 depletion indicated that the role of GPR30 was to promote SKBr3 cell growth but reduce MCF-7 cell growth. Supporting this, G-1 profoundly inhibited MCF-7 cell growth, potentially via p53 and p21 induction. Further, flow cytometry showed that G-1 blocked MCF-7 cell cycle progression at the G<sub>1</sub> phase. Thus, GPR30 antagonizes growth of ERα-positive breast cancer and may represent a new target to combat this disease. Cancer Res; 70(3); 1184–94</p></div>